Differential Regulation of Growth and Invasiveness of MCF-7 Breast Cancer Cells by Antiestrogens

Cancer Research

Volumn 48, Issue 23, 1988, Pages 6764-6768

  Thompson, Erik W ^a   Reich, Reuven ^a   Shima, Thomas B ^a   Albini, Adriana ^a   Graf, Jeannette ^a   Martin, George R ^a   Dickson, Robert B ^a   Lippman, Marc E ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ANTIESTROGEN; COLLAGENASE; ESTRADIOL; RALOXIFENE; TAMOXIFEN;

BREAST CANCER CELL; CELL CULTURE; CELL GROWTH; CELL INVASION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL DIVISION; CHEMOTAXIS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMAN; MICROBIAL COLLAGENASE; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATORS; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0024210084     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Soule, H. D., Vasquez, J., Long, A., Albert, S., and Brennan, M. J. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst, 51:1409-1416, 1973.
2. Lippman, M. E., Bolan, G., and Huff, K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term culture. Cancer Res., 36:4610-4618, 1976.
3. Horowitz, K. B., and McGuire, W. L. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J. Biol. Chem., 253:2223-2228, 1978.
4. Westley, B., and Rochefort H. Estradiol induced proteins in MCF-7 human breast cancer cell line. Biochem. Biophys. Res. Commun., 90: 410–416, 1979.
5. Dickson, R. B., and Lippman, M. E. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrine Rev., 8:29-43, 1987.
6. Soule, H. D., and McGrath, C. M. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett., 10: 177–189, 1980.
7. Osborne, C. K., Hobbs, K., and Clark, G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res., 45:584-590, 1985.
8. Lippman, M. E., Bolan, G., Monaco, M. E., Pinkus, L., and Engel, E. Model systems for the study of estrogen action in tissue culture. J. Steroid Biochem., 7:1045-1051, 1976.
9. Aitken, S. C., and Lippman, M. E. Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res., 45:1611-1620, 1985.
10. Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J., and Berthois, Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res., 47:4355-4360, 1987.
11. Cailleau, R., Young, R., Olive, M., and Reeves, W. J., Jr. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst., 53:661-674, 1974.
12. Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E. R., Plotkin, D., Bowman, D., Sachs, S., Wolter, J., Frelick, R., Desser, R., LiCalzi, N., Geggie, P., Campbell, T., Elias, E. G., Prager, D., Koontz, P., Volk, H., Dimitrov, N., Gardner, B., Lerner, H., and Shibata, H. Treatment of primary breast cancer with chemotherapy and tamoxifen. N. Engl. J. Med., 305:1-6, 1981.
13. Heuson, J. C. Current overview of EORTC clinical trials with tamoxifen. Cancer Treat. Rep., 60:1463-1466, 1976.
14. Horowitz, K. B., and McGuire, W. L. Antiestrogens: mechanism of action and effects in breast cancer. In: W. L. McGuire (ed.), Breast Cancer: Advances in Research and Treatment Vol. 2, pp. 155–204. New York: Plenum Publishing Corp., 1978.
15. Tormey, D. C., Simon, R. M., Lippman, M. E., Bull, J. M., and Myers, C. E. Evaluation of tamoxifen dose in advanced breast cancer a progress report. Cancer Treat. Rep., 60:1451-1459, 1976.
16. Sonnenschein, C., Papendorp, J. T., and Soto, A. M. Estrogenic effect of tamoxifen and its derivations on the proliferation of MCF-7 human breast tumor cells. Life Sci., 37:387-394, 1985.
17. Reddel R. R., and Sutherland, R. L. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur. J. Cancer Clin. Oncol., 20:1419-1424, 1984.
18. Darbre, P., Yates, Y., Curtis, S., and King, R. J. B. Effect of estradiol on human breast cancer cells in culture. Cancer Res., 43:349-354, 1983.
19. Osborne, C. K., Coronado, E. B., and Robinson, J. R. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol., 23:1189-1196, 1987.
20. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in the athymic mouse. Proc. Am. Assoc. Cancer Res., 29:233, 1988.
21. Sapino, A., Pietribiasi, F., Rhusolti, G., and Marchosio, P. C. Estrogen- and tamoxifen-induced rearrangements of cytoskeletal and adhesion structure in breast cancer MCF-7 cells. Cancer Res., 46:2526-2531, 1986.
22. Berthois, Y., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA, 83: 2496-2500, 1986.
23. Lyman, S. D., and Jordan, V. C. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus. Biochem. Pharmacol., 34:2795-2806, 1985.
24. Jordan, V. C., Haldemann, B., and Allen, K. E. Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology, 108: 1353-1361, 1981.
25. Black, L. J., and Goode, R. L. Uterine bioassay of tamoxifen, trioxifene, and a new estrogen antagonist (LY117018) in rats and mice. Life Sci, 26:1453-1458, 1980.
26. Dix, C. J., and Jordan, V. C. Subcellular effects of monohydroxytamoxifen in the rat uterus: steroid receptors and mitosis. J. Endocrinol, 85:393-404, 1980.
27. Koseki, Y., Zava, D. T., Chamness, G. C., and McGuire, W. L. Progesterone interaction with estrogen and antiestrogen in the rat uterus-receptor effects. Steroids, 30:169-177, 1977.
28. Leavitt, W. W., Chen, T. J., and Allen, T. C. Regulation of progesterone receptor formation by estrogen action. Ann. NY Acad. Sci, 286: 210–225, 1977.
29. Jordan, V. C., and Prestwich, G. Effect of non-steroidal antiestrogens on the concentration of rat uterine progesterone receptors. J. Endocrinol., 76: 363-364, 1978.
30. Westley, B., May, F. E., Brown, M. C., Krust, A., Chambon, P., Lippman, M. E., and Rochefort, H. Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52 and 160-kilodalton proteins in MCF-7 cells and two tamoxifen-resistant sublines. J. Biol. Chem., 259:10030-10035, 1984.
31. May, F. E. B., and Westley, B. R. Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells. J. Biol. Chem., 262:15894-15899, 1987.
32. Albini, A., Graf, J. G., Kitten, G. T., Kleinman, H. K., Martin, G. R., Veillette, A., and Lippman, M. E. 170-Estradiol regulates and γ-Ha-ros transfection constitutively enhances MCF-7 breast cancer cell interactions with basement membrane. Proc. Natl. Acad. Scl USA, 83:8182-8186, 1986.
33. Thorgeirsson, U. P., Turpeenniemi-Hujanen, T., and Liotta, L. A. Cancer cells, components of basement membranes, and proteolytic enzymes. Int Rev. Exp. Pathol., 27:203-234, 1985.
34. Black, L. J., and Goode, R. L. Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms. Endocrinology, 709:987-989, 1981.
35. Scholl, S. M., Huff, K. K., and Lippman, M. E. Antiestrogenic effects of LY117018 in MCF-7 cells. Endocrinology, 113:611-617, 1983.
36. Wakeling, A. E., Valcarcia, B., Newboult, E., and Green, L. R. Nonsteroidal antiestrogens: receptor binding and biological response in rat uterus, rat mammary carcinoma, and human breast cancer cells. J. Steroid Biochem., 20:111-120, 1984.
37. Albini, A., Iwamoto, Y., Kleinman, H. K., Martin, G. R., Aaronson, S. A., Kozlowski, J. M., and McEwan, R. N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res., 47:3239-3245, 1987.
38. Kleinman, H. K., McGarvey, M. L., Hassell, J. R., Star, V. L., Cannon, F. B., Laurie, G. W., and Martin, G. R. Basement membrane complexes with biological activity. Biochemistry, 25:312-318, 1986.
39. Menzel, J., and Borth, W. Influence of plasma fibronectin on collagen cleavage by collagenase. Coll. Rel. Res., 3:217-230, 1983.
40. Kleinman, H. K., McGarvey, M. L., Liotta, L. A., Gehron-Robey, P. Tryggvason, K., and Martin, G. R. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry, 24: 6188-6193, 1982.
41. Kasid, A., Lippman, M. E., Papageorge, A. G., Lowy, D. W., and Gelman, E. P. Transfection of v-rar” DNA into MCF-7 cells bypasses their dependence on estrogen for tumorigenicity. Science (Wash. DC), 228: 725–728, 1985.
42. Kasid, A., Knabbe, C., and Lippman, M. E. Effect of V-rar” oncogenes transfection on estrogen-independent tumorigenicity of estrogen-dependent human breast cancer cells. Cancer Res., 47:5733-5738, 1987.
43. Sutherland, R. H., Murphy, L. C., Roo, M. S., Green, M. D., and Whybourne, A. M. High affinity anti-estrogen binding site distinct from the estrogen receptor. Nature (Lond.), 288:273-275, 1980.
44. Sheen, Y. Y., Simpson, D. M., and Katzenellenbogen, B. S. An evaluation of the role of antiestrogen binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor. Endocrinology, 117: 561-564, 1985.
45. Sutherland, R. L., Watts, C. K. W., and Ruenitz, P. C. Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor. Biochem. Biophys. Res. Commun., 140:523-529, 1986.
46. Reich, R., Thompson, E. W., Iwamoto, Y., Martin, G. R., Deason, J., Fuller, G. E., and Mislkin, R. Inhibitors of plasminogen activator, serine proteases, and collagenase IV prevent the invasion of basement membranes by metastatic cells. Cancer Res., 48:3307-3312, 1988.
47. Turpeenniemi-Hujanen, T., Thorgeirsson, U. P., Rao, C. N., and Liotta, L. A. Laminin increases the release of type IV collagenase from malignant cells. J. Biol. Chem., 261:1883-1889, 1986.
48. Mignatti, P., Robbins, E., and Rifkin, D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47: 487-498, 1986.
49. Kao, R., and Stem, R. Collagenases in human breast carcinoma cell lines. Cancer Res., 46:1349-1354, 1986.
50. Paraqjpe, M., Engle, L., Young, L., and Liotta, L. A. Activation of human breast carcinoma collagenase through plaminogen activator. Life Sci, 26: 1223-1231, 1980.
51. Huff, K. K., and Lippman, M. E. Hormonal control of plasminogen activator secretion in ZR75-1 human breast cancer cells in culture. Endocrinology, 114:1702-1710, 1984.
52. Butler, W. B., Kirkland, W. L., and Joigensen, T. L. Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). Biochem. Biophys. Res. Commun., 90:1328-1334, 1979.
53. Kneifel, A., Leytus, S. P., Fletcher, E., Weber, T., Mangel, W. F., and Katzenellenbogen, B. S. Serine plasminogen activator activity: modulation by steroid hormones. Endocrinology, 111: 493-499, 1982.
54. Katzenellenbogen, B. S., Norman, M. J., Eckert, R. L., Peltz, S. W., and Mangel, W. F. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res., 44:112-119, 1984.
55. Fentimen, I. S., and Powles T. J. Tamoxifen and benign breast problems. Lancet, 2:1070-1071, 1987.
56. Henderson, I. C. Endocrine therapy in metastatic breast cancer. In: J. R. Harris, S. Heilman, I. C. Henderson, and D. W. Kinne (eds.), Breast Diseases. Philadelphia: J. B. Lippincott Co., 1987.
57. Legault-Poisson, S., Jolivet, J., Poisson, R., Beretta-Piccoli, M., and Band, P. R. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat Rep., 63:1839-1841, 1979.
58. patients 58. Jordan, V. C., Fritz, N. F., and Tormey, D. C. Endocrine effects of adjuvant chemotherapy and long term tamoxifen administration in node positive with breast cancer. Cancer Res., 47:624-630, 1987.
59. Sakai, F., Cheix, F., Clavel, M., Colon, J., Mayer, M., Pannata, E., and Saez, S. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast J. EndocrinoL, 76:219-226, 1978.
60. Szamel I., Vincze, B., Hindy, I., Hermann, I., Borvendeg, J., and Eckhardt, S. Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer. Oncology (Basel), 43:7-11, 1986.
61. Jordan, V. C., Fritz, N. F., and Tormey, D. C. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin Cancer Res., 47:4517-4519, 1987.
62. Gottardis, M. M., and Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47:4020-4024, 1987.
63. Jordan, V. C., Fritz, N. F., and Gottardis, M. M. Strategies for breast cancer therapy with antiestrogens. J. Steroid Biochem., 27:493-498, 1987.
64. Gottardis, M. M., Robinson, S. P., and Jordan, V. C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J. Steroid Biochem., 30:311-314, 1988.